We are live on ! Find out more
ARIA

Ariad Pharmaceuticals Inc
ARIA

Delisted

ARIA was delisted on the 15th of February, 2017.

Back to rankings

169 hedge funds and large institutions have $790M invested in Ariad Pharmaceuticals Inc in 2014 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 63 increasing their positions, 44 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 44

19% more call options, than puts

Call options by funds: $31.5M | Put options by funds: $26.5M

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

7% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 29

1% less funds holding

Funds holding: 171 → 169 (-2)

10% less capital invested

Capital invested by funds: $877M → $790M (-$86.6M)

Holders
169
Holders Change
-2
Holders Change %
-1.17%
% of All Funds
4.86%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.11%
New
27
Increased
63
Reduced
44
Closed
29
Calls
$31.5M
Puts
$26.5M
Net Calls
+$5.02M
Net Calls Change
+$1.41M

Top Buyers

Rank Fund Capital Flow
1
AQR Capital Management
AQR Capital Management
Connecticut
+$20.4M
2
BFA
BlackRock Fund Advisors
California
+$19.5M
3
Renaissance Technologies
Renaissance Technologies
New York
+$14.8M
4
Norges Bank
Norges Bank
Norway
+$14.6M
5
CCM
Camber Capital Management
Massachusetts
+$13.8M

Top Sellers

Rank Fund Capital Flow
1
SPC
Slate Path Capital
New York
-$53.4M
2
PAI
Palo Alto Investors
California
-$8.14M
3
ARTA
A.R.T. Advisors
New York
-$4.58M
4
Citadel Advisors
Citadel Advisors
Florida
-$3.23M
5
Allianz Asset Management
Allianz Asset Management
Germany
-$2.81M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$85.2M – – –
SCM
2
Sarissa Capital Management
Connecticut
$76.4M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$67.9M +$1.87M +271,561 +3%
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$50.8M +$8.94M +1,300,000 +19%
BFA
5
BlackRock Fund Advisors
California
$41M +$19.5M +2,832,609 +79%
State Street
6
State Street
Massachusetts
$36.8M +$6.36M +925,082 +19%
Franklin Resources
7
Franklin Resources
California
$32.1M -$792K -115,200 -2%
CCM
8
Camber Capital Management
Massachusetts
$31.9M +$13.8M +2,000,000 +67%
BIT
9
BlackRock Institutional Trust
California
$30.8M +$1.71M +248,617 +5%
Renaissance Technologies
10
Renaissance Technologies
New York
$28M +$14.8M +2,151,135 +96%
Norges Bank
11
Norges Bank
Norway
$27.1M +$14.6M +2,123,115 +100%
AQR Capital Management
12
AQR Capital Management
Connecticut
$24.7M +$20.4M +2,959,312 +320%
PAI
13
Palo Alto Investors
California
$14.5M -$8.14M -1,183,021 -34%
PC
14
PointState Capital
New York
$12.4M +$9.28M +1,350,000 +225%
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
$11.4M +$2.86M +415,931 +30%
OM
16
Opaleye Management
Massachusetts
$10.6M -$68.8K -10,000 -0.6%
Ameriprise
17
Ameriprise
Minnesota
$10.3M +$2.41M +350,740 +28%
Morgan Stanley
18
Morgan Stanley
New York
$8.96M +$5.66M +822,432 +141%
HM
19
HealthCor Management
New York
$8.6M +$9.28M +1,350,000 New
GAI
20
General American Investors
New York
$7.64M – – –
Deutsche Bank
21
Deutsche Bank
Germany
$6.74M -$1.58M -229,665 -18%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$6.42M +$747K +108,640 +12%
SFM
23
Soros Fund Management
New York
$6.37M +$3.44M +500,000 +100%
CC
24
CQS Cayman
Cayman Islands
$6.37M +$6.88M +1,000,000 New
Bank of New York Mellon
25
Bank of New York Mellon
New York
$6.29M +$1.83M +265,438 +37%
1
2 3 4 5

ARIA Hedge Fund Activity: Q2 2014 in Review

169 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q2 2014, worth a combined $790M — down 9.9% from $877M a quarter earlier.

Sellers outnumbered buyers: 29 funds closed out of ARIA and 27 opened new positions — a net loss of 2 holders — while 44 trimmed existing stakes and 63 added.

The largest buyer was AQR Capital Management, adding an estimated $20.4M. The largest seller was Slate Path Capital, exiting entirely with an estimated $53.4M sold.

  • 169 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q2 2014, down from 171 in Q1 2014.
  • Funds reported $790M of Ariad Pharmaceuticals Inc stock for Q2 2014, down 9.9% quarter-over-quarter.
  • 27 funds opened new Ariad Pharmaceuticals Inc positions in Q2 2014 and 29 closed out, a net change of -2 holders.
  • The largest Ariad Pharmaceuticals Inc buyer in Q2 2014 was AQR Capital Management, an estimated $20.4M added.
  • The largest Ariad Pharmaceuticals Inc seller in Q2 2014 was Slate Path Capital, an estimated $53.4M sold.

Based on aggregated 13F filings for Q2 2014.